Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion
Mb. Reed et al., Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion, P NAS US, 97(13), 2000, pp. 7509-7514
Citations number
32
Categorie Soggetti
Multidisciplinary
Journal title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Erythrocyte invasion by Plasmodium requires molecules present both on the m
erozoite surface and within the specialized organelles of the apical comple
x. The Plasmodium erythrocyte binding protein family includes the Plasmodiu
m falciparum sialic acid-binding protein, EBA-175 (erythrocyte binding anti
gen-175). which binds sialic acid present on glycophorin A of human erythro
cytes. We address the role of the conserved 3'-cysteine rich region, the tr
ansmembrane, and cytoplasmic domains through targeted gene disruption. Trun
cation of EBA-175 had no measurable effect on either the level of EBA-175 p
rotein expression or its subcellular localization. Similarly, there appears
to be no impairment in the ability of soluble EBA-175 to be released into
the culture supernatant after schizont rupture. Additionally, the 3'-cys ri
ch region, transmembrane. and cytoplasmic domains of EBA-175 are apparently
non-essential for merozoite invasion. In contrast, erythrocyte invasion vi
a the EBA-175/glycophorin A route appears to have been disrupted to such a
degree that the mutant lines have undergone a stable switch in invasion phe
notype, As such, EBA-175 appears to have been functionally inactivated with
in the truncation mutants. The sialic acid-independent invasion pathway wit
hin the mutant parasites accounts for approximately 85% of invasion into no
rmal erythrocytes, These data demonstrate the ability of P, falciparum to u
tilize alternate pathways for invasion of red blood cells, a property that
most likely provides a substantial survival advantage in terms of overcomin
g host receptor heterogeneity and/or immune pressure.